search
Back to results

Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus (T2DM)

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
Inhaled Human Insulin
Insulin Lispro (Humalog U-100)
Sponsored by
Dance Biopharm Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Inhaled Insulin

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subjects diagnosed with T2DM.
  • BMI between 25.0 and 40.0 kg/m2.
  • Treated with metformin and/or at least 1 daily injection of insulin for at least 6 months.
  • Non-smoker for at least 5 years.
  • Forced vital capacity and forced expiratory volume in one second is at least 75% normal.

Exclusion Criteria:

  • Any condition affecting pulmonary drug absorption.
  • History or presence of cancer except basal cell skin cancer or squamous cell skin cancer.
  • Serious systemic infectious disease during four weeks prior to dosing.
  • Clinically significant abnormal lab values.
  • Proliferative retinopathy and/or severe neuropathy.
  • Recurrent severe hypoglycemia.
  • Current treatment with oral anti-diabetic drugs except metformin, glucagon-like peptide receptor agonists.
  • Current treatment with MAO inhibitors.
  • Unstable Thyroid hormones for at least 3 months.
  • Insufficient glycemic control with significant fluctuations of blood glucose.

Sites / Locations

  • Profil Mainz

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Dance 501

Insulin Lispro

Arm Description

Dance 501(Human Insulin Inhalation Solution and Inhaler) will be administered using the Dance 501 Inhaler.

Insulin Lispro (Humalog®) will be administered by subcutaneous injection.

Outcomes

Primary Outcome Measures

Primary Pharmacokinetic Endpoint - PK 1
Area under the human insulin and insulin lispro concentrations time curves
Primary Pharmacokinetic Endpoint - PK 2
Maximum observed concentration of human insulin and insulin lispro
Primary Pharmacodynamic Endpoint - PD 1
Area under the glucose infusion rate time curve
Primary Pharmacodynamic Endpoint - PD 2
Maximum observed glucose infusion rate

Secondary Outcome Measures

Secondary Pharmacokinetic Endpoint - PK 1
Area under the insulin time curves at different intervals
Secondary Pharmacokinetic Endpoint - PK 2
Time to maximum insulin concentrations
Secondary Pharmacokinetic Endpoint - PK 3
Relative Efficiency of dose corrected ratio of AUC ins for INH and s.c. lispro
Secondary Pharmacokinetic Endpoint - PK 4
Onset of appearance (time from trial product administration until the serum insulin concentrations are > LLOQ.
Secondary Pharmacokinetic Endpoint - PK 5
Mean residence time of insulin
Secondary Pharmacodynamic Endpoint - PD 1
AUC for GIR at different time intervals
Secondary Pharmacodynamic Endpoint - PD2
Time to maximum glucose infusion rate
Secondary Pharmacodynamic Endpoint - PD3
Relative biopotency of dose corrected ratio of AUC GIR for INH and s.c. lispro

Full Information

First Posted
February 25, 2019
Last Updated
September 20, 2019
Sponsor
Dance Biopharm Inc.
Collaborators
Profil Institut für Stoffwechselforschung GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT04100473
Brief Title
Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus
Acronym
T2DM
Official Title
A Randomized, Open-Label, 6-Period Cross-Over Study to Investigate the Dose Response of Dance 501 (Human Insulin Inhalation Solution and Inhaler) in Subjects With Type 2 Diabetes Mellitus (T2DM)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2019
Overall Recruitment Status
Completed
Study Start Date
April 23, 2018 (Actual)
Primary Completion Date
August 11, 2018 (Actual)
Study Completion Date
August 1, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dance Biopharm Inc.
Collaborators
Profil Institut für Stoffwechselforschung GmbH

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This will be a randomized, open-label, active-controlled, 6-period crossover study. Target population will be subjects with Type 2 Diabetes Mellitus (T2DM)
Detailed Description
To assess the dose-response and dose-exposure of Dance 501 (Human Insulin Inhalation Solution) administered with the Dance 501 Inhaler.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Inhaled Insulin

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Model Description
Randomized, Open-Label, Cross-Over design
Masking
None (Open Label)
Allocation
Randomized
Enrollment
24 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dance 501
Arm Type
Experimental
Arm Description
Dance 501(Human Insulin Inhalation Solution and Inhaler) will be administered using the Dance 501 Inhaler.
Arm Title
Insulin Lispro
Arm Type
Active Comparator
Arm Description
Insulin Lispro (Humalog®) will be administered by subcutaneous injection.
Intervention Type
Drug
Intervention Name(s)
Inhaled Human Insulin
Other Intervention Name(s)
Dance 501
Intervention Description
Dance 501 administered using the Dance 501 Inhaler
Intervention Type
Drug
Intervention Name(s)
Insulin Lispro (Humalog U-100)
Other Intervention Name(s)
Insulin Lispro (Humalog U-100) will be administered by subcutaneous injection
Intervention Description
Lispro
Primary Outcome Measure Information:
Title
Primary Pharmacokinetic Endpoint - PK 1
Description
Area under the human insulin and insulin lispro concentrations time curves
Time Frame
0 - 10 hours
Title
Primary Pharmacokinetic Endpoint - PK 2
Description
Maximum observed concentration of human insulin and insulin lispro
Time Frame
0 - 10 hours
Title
Primary Pharmacodynamic Endpoint - PD 1
Description
Area under the glucose infusion rate time curve
Time Frame
0 - 10 hours
Title
Primary Pharmacodynamic Endpoint - PD 2
Description
Maximum observed glucose infusion rate
Time Frame
0 - 10 hours
Secondary Outcome Measure Information:
Title
Secondary Pharmacokinetic Endpoint - PK 1
Description
Area under the insulin time curves at different intervals
Time Frame
0 - 1 hour, 0 - 2 hours, 0 - 8 hours
Title
Secondary Pharmacokinetic Endpoint - PK 2
Description
Time to maximum insulin concentrations
Time Frame
0 - 10 hours
Title
Secondary Pharmacokinetic Endpoint - PK 3
Description
Relative Efficiency of dose corrected ratio of AUC ins for INH and s.c. lispro
Time Frame
0 - 10 hours
Title
Secondary Pharmacokinetic Endpoint - PK 4
Description
Onset of appearance (time from trial product administration until the serum insulin concentrations are > LLOQ.
Time Frame
0 - 10 hours
Title
Secondary Pharmacokinetic Endpoint - PK 5
Description
Mean residence time of insulin
Time Frame
0 - 10 hours
Title
Secondary Pharmacodynamic Endpoint - PD 1
Description
AUC for GIR at different time intervals
Time Frame
0 - 1 hour, 0 - 2 hours, 0 - 8 hours
Title
Secondary Pharmacodynamic Endpoint - PD2
Description
Time to maximum glucose infusion rate
Time Frame
0 - 10 hours
Title
Secondary Pharmacodynamic Endpoint - PD3
Description
Relative biopotency of dose corrected ratio of AUC GIR for INH and s.c. lispro
Time Frame
0 - 10 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects diagnosed with T2DM. BMI between 25.0 and 40.0 kg/m2. Treated with metformin and/or at least 1 daily injection of insulin for at least 6 months. Non-smoker for at least 5 years. Forced vital capacity and forced expiratory volume in one second is at least 75% normal. Exclusion Criteria: Any condition affecting pulmonary drug absorption. History or presence of cancer except basal cell skin cancer or squamous cell skin cancer. Serious systemic infectious disease during four weeks prior to dosing. Clinically significant abnormal lab values. Proliferative retinopathy and/or severe neuropathy. Recurrent severe hypoglycemia. Current treatment with oral anti-diabetic drugs except metformin, glucagon-like peptide receptor agonists. Current treatment with MAO inhibitors. Unstable Thyroid hormones for at least 3 months. Insufficient glycemic control with significant fluctuations of blood glucose.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Oliver Klein
Organizational Affiliation
Profil Institut fur Stoffwechselforschung GmbH
Official's Role
Principal Investigator
Facility Information:
Facility Name
Profil Mainz
City
Mainz
State/Province
Malakoff-Passage
Country
Germany

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus

We'll reach out to this number within 24 hrs